Eliana Aparecida Varanda

• Abstract

  The apparent incompatibility between chemical and pharmacological investigation of a plant species can be solved with the strong determination of dealing rationally with the problem. The research groups on Natural Products Chemistry from the IQ-Araraquara-Unesp, on Pharmacology, from IB-Unicamp and 1B-Botucatu-Unesp and on Biological Sciences, from FCF-Araraquara-Unesp have started a coll…

  Sustainable use of the Brazilian biodiversity: chemical and pharmacological prospection on higher plants, AP.BTA.TEM

• Abstract

  The Brazilian cerrado contains many popular plants used in the treatment of various diseases. The genus Byrsonima is one of them. There are several reports of its use: the treatment of fungal and bacterial infections, chronic wounds, Chagas disease, TB, as a diuretic, antiemetic, and so on. In the literature, there is evidence for activities: antioxidant, antiprotozoal, CNS depressant, an…

  Evaluation of mutagenicity, antimutagenicity and estrogenicity of Byrsonima species, BP.MS

• Abstract

  The program "BIOTA/FAPESP" aims to identify and characterize the biodiversity of the State of São Paulo, defining the mechanisms for its conservation, economic potential and sustainable use. Some preliminary studies considering the biological activities of plant extracts were performed in the first stage of the project, however, their registration requires the assessment of herbal extract…

  Standardized phytoterapics for the treatment of chronic diseases: Cytotoxic, mutagenic and protective properties and the modulation of gene expression, BP.PD

• Abstract

  Plants are an important source of biologically active natural products, many of which are used as models for the synthesis of a large number of drugs. These natural products show an almost inexhaustible range of diversity in structure and physicochemical and biological properties. However, out of an estimated 250,000 species of higher plants in the world, only 10% have been investigated b…

  Herbal standardized for the treatment of chronic diseases: Evaluation of mutagenic and estrogenic activities and in vitro bioavailabity, BP.PD

(Only some records are available in English at this moment)